Search

Pro,state cancer is the .second most common cancer in men and the fifth leading cau.se of cancer deaths in men.Although there is an initial response to traditional treatments which include radical prostatectomy, chemotherapy, androgen deprivation therapy, and so on, some patients eventually progress to castration-resistant prostate cancer. The human immune system can perform a monitoring function to kill tumor cells promptly, however,tumor cells also express PD-L1 as they evolve, which binds to PD-1 on T cells and can inhibit T cell function, ultimately inducing immune evasion. The in-depth study of PD-1/PD-L1 in the mechanism of immune evasion in prostate cancer may provide new therapeutic strategies for the future application of PD-1/ PD-L1-based immunotherapy in prostate cancer treatment. In this paper, we will review the latest research progress of PD-1/ PD-L1 in prostate cancer immunotherapy. [ABSTRACT FROM AUTHOR]

Myasthenia gravis (MG) is an autoimmune disease mediated by anti-acetylcholine receptor (AChR) antibodies and dependent on CD4 positive T lymphocytes (CD4+T) cells. MicroRNA (miRNA) is an endogenous small single-stranded non-coding RNA that involved in post-transcriptional regulation and plays an important role in differentiation and function of CD4+T cells. Increasing evidences have shown that changes of miRNAs happened in MG patients, which may participate in the occurrence and development of MG by regulating CD4+T cells, and miRNA may be a potential therapeutic target for MG. In this paper, relationship between miRNA and MG was reviewed in order to provide new ideas for further research on the pathogenesis and clinical diagnosis and treatment of MG. [ABSTRACT FROM AUTHOR]